H.C. Wainwright initiated coverage of Mural Oncology with a Buy rating and $18 price target Mural’s nemvaleukin alfa, an engineered interleukin-2 cytokine, is designed to harness the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its typical toxic side effects, the analyst tells investors in a research note. The firm projects initial nemvaleukin sales of $3.6M in the second half of 2026, growing to peak U.S. sales of $676M across indications by 2035.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MURA:
- Mural Oncology initiated with a Strong Buy at Raymond James
- Mural Oncology ‘undervalued,’ initiated with Strong Buy at Raymond James
- Mural Oncology’s Investor Day Highlights Cancer Treatment Trials
- Mural Oncology provides update on ARTISTRY-7 at Investor Day
- Mural Oncology provides update on ARTISTRY-6 cohort 2 at Investor Day
Questions or Comments about the article? Write to editor@tipranks.com